PDF (Español (España))
FLIP
HTML (Español (España))
EPUB (Español (España))
Manuscripts sent to SALUTA Magazine must be original and unpublished and must not be simultaneously in the process of publication in other magazines, compilations or any other means of publication. The content of the publications and the links suggested in them are the sole responsibility of the authors and not of the METROPOLITAN UNIVERSITY OF EDUCATION, SCIENCE AND TECHNOLOGY
(UMECIT) or the magazine SALUTA. They are protected by international copyright laws as well as the logos of UMECIT AND SALUTA MAGAZINE, hence their reproduction is totally prohibited. The copyright will belong to the UMECIT.
Under a Creative Commons Attribution License authors may share work with acknowledgment of authorship of the work and initial publication in this journal.
Abstract
Alzheimer’s is a degenerative neurocognitive disorder that affects the execution and memory functions of people who suffer from it, this means that they are unable to perform simple activities in their jobs and even in their self-care, forget people close to them and that progressively become dependent on the care of other people. This pathology represents the main cause of dementia worldwide in adults over 60 years of age and its causes are unknown but it is attributed as a risk factor advanced age, recurrent cranial lesions, alterations with the E4 apolipoprotein and in patients with genetic alterations such as trisonomy 21 and cerebrovascular diseases. The diagnosis of this pathology is made regularly in the most advanced stages of the disease because people confuse the first symptoms and signs as characteristic of a normal aging and when being detected it is very complicated to be able to handle the disease. It is estimated that the application of research programs and projects focused on developing cost-effective approaches to detect this neurocognitive condition in the early stages is of utmost importance, becoming an essential step towards reducing the burden of the disease. Some studies conducted by the Panamanian program PARI (Panama Aging Research Initiative) indicate that the main obstacle to the diagnosis and effective treatment of Alzheimer’s disease is the lack of readily available biomarkers. It is shown that through cerebral images and biomarkers of cerebrospinal fluid are very accurate in the detection of the disease. It is very important to assess the impact of this condition on the families of the patients, remembering that they must be enriched with a series of tools and methods that allow them to help their family member to lead an adequate quality of life despite their suffering and avoiding overloads and frustration in direct caregivers by not knowing how to handle the progressive and degenerative changes of the patient, as well as psychological assistance that will help them to face the different adaptations that will appear in the family environment.
References
2. Carretero, V y colaboradores. (s.f.). Guía práctica para enfermos de Alzheimer. Fundación de PwC. (Datos en línea). Disponible: http://www.crealzheimer.es (consulta: 5 de junio 2017)
3.Enfermedad de Alzheimer. Revista de Posgrado de la VI a Cátedra de Medicina. (Datos en línea). Disponible: http://www.ncbi.nlm.nih.gov/books/ bv.fcgi?rid=hstat6.section.38720 (consulta: 5 de junio 2017)
4.Fontán, L. (2012). La enfermedad de Alzheimer: elementos para el diagnóstico y manejo clínico en el consultorio. Medicina familiar y comunitaria. (Datos en línea) Disponible: http://www.imserso.es (consulta: 5 de junio 2017)
5.La enfermedad de Alzheimer. (2010). Instituto Nacional sobre el Envejecimiento. (Datos en línea). Disponible: www.nih.gov/Alzheimers/Publications/adfact.htm (consulta: 2 de junio 2017)
6.La enfermedad de Alzheimer. (2011). Alzheimer´s Association (datos en línea) Disponible: http://www.alz.org/espanol/about/el_alzheimer_y_el_cerebro.asp (consulta: 5 de junio 2017)
7.Manual diagnóstico y estadístico de los trastornos mentales DSM V. (2013). American Psychiatric Association. Quinta Edición. Editorial Medica Paramericana (Libro en línea). Disponible: vvww.medicapanamericana.com (consulta: 1 de junio 2017)
8.Mitchell, A. (2014). Hay 22 mil casos de Alzheimer en Panamá. Diario Panamá América. (Datos en línea). Disponible en: http://www.panamaamerica.com.pa/ey/hay22-mil-casos-de-alzheimer-en-panama (consulta: 14 de diciembre 2017) Parquet, C. (2007).
